一种用于瘤化学栓塞的新型凝聚体栓塞剂
Menghui Liu1,2,3, Yang Sun1,2,3, Yitong Zhou1,2
1Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, 519000, China.
Advanced healthcare materials
|April 8, 2024
概括
这项研究引入了一种新型的协同体栓塞剂,用于跨导管动脉化学栓塞 (TACE). 这种新药有效地提供化疗药物,有望改善瘤治疗.
科学领域:
- 生物材料科学 生物材料科学
- 在瘤学瘤学.
- 干预性放射学 干预性放射学
背景情况:
- 传统的跨导管动脉化学栓塞剂 (TACE) 在药物加载,持续释放,生物降解性和机械稳定性方面存在局限性.
- 现有的药物往往因聚合和不稳定性质而扎,阻碍了最佳的治疗结果.
研究的目的:
- 开发和评估一种新的复杂的基于协酸盐的液体栓塞剂,以改善瘤化学栓塞.
- 通过增强药物输送和持续释放来解决传统TACE药物的局限性.
主要方法:
- 通过混合四分化奇托 (QCS) 和阿拉伯糖 (GA) 形成一个复杂的协体,表现出剪切稀释特性.
- 克索 (I) 和多克索鲁比辛 (DOX) 被纳入QCS/GA联合体中,以创建X射线不透明的,携带药物的栓塞剂 (QCS/GA/I/DOX).
- 该药物的有效性在子模型中被测试用于栓塞脏动脉和VX2瘤供应动脉.
主要成果:
- 在QCS/GA/I/DOX协体中,表现出有效的动脉栓塞,而无需重新道化.
- 在子耳朵和肝脏模型中,成功地实现了VX2瘤食动脉的栓塞.
- 协酸促进了局部多克索鲁比辛的释放,增强了抗瘤功效,具有出色的生物相容性和生物降解性.
结论:
- 与传统药物相比,新型QCS/GA/I/DOX联合体栓塞剂提供了优越的药物加载和持续释放能力.
- 这种创新的配方显示出有效和安全的瘤化学栓塞的巨大潜力,并具有用户友好的应用.
- 剪切稀释性,生物相容性和生物降解性使这种协同植物成为癌症治疗中的有希望的进步.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160
01:27Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
198
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
274
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
274
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
246
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
246
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K